Eyebright Medical Technology Beijing Co Ltd Total Assets
Eyebright Medical Technology Beijing Co Ltd total assets. Based on the latest financial reports, Eyebright Medical Technology Beijing Co Ltd (688050) holds total assets worth CN¥4.76 Billion CNY (≈ $697.26 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see 688050 stock market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of Eyebright Medical Technology Beijing Co Ltd (2016–2025)
Total assets of Eyebright Medical Technology Beijing Co Ltd from 2016 to 2025. This chart illustrates how Eyebright Medical Technology Beijing Co Ltd's total assets have evolved over time, based on quarterly financial data. See Eyebright Medical Technology Beijing Co share price for real-time trading data and today's change.
Eyebright Medical Technology Beijing Co Ltd - Asset Composition Analysis
Eyebright Medical Technology Beijing Co Ltd Total Assets Breakdown (December 2025)
Eyebright Medical Technology Beijing Co Ltd total assets breakdown as of December 2025. Eyebright Medical Technology Beijing Co Ltd's total assets of CN¥4.76 Billion consist of 43.0% current assets and 57.0% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 16.2% |
| Accounts Receivable | CN¥470.46 Million | 12.1% |
| Inventory | CN¥313.22 Million | 8.1% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥356.81 Million | 9.2% |
| Goodwill | CN¥148.77 Million | 3.8% |
Asset Composition Trend (2016–2025)
This chart illustrates how Eyebright Medical Technology Beijing Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore 688050 working capital efficiency to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Eyebright Medical Technology Beijing Co Ltd's current assets represent 43.0% of total assets in 2025, an increase from 36.1% in 2016.
- Cash Position: Cash and equivalents constituted 16.2% of total assets in 2025, down from 18.3% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 12.0% of total assets, a decrease from 21.0% in 2016.
- Asset Diversification: The largest asset category is accounts receivable at 12.1% of total assets.
Eyebright Medical Technology Beijing Co Ltd Competitors by Total Assets
Key competitors of Eyebright Medical Technology Beijing Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Imeik Technology Development Co
SHE:300896
|
China | CN¥9.13 Billion |
|
Shenyang Xingqi Pharmaceutical Co Ltd
SHE:300573
|
China | CN¥2.42 Billion |
|
SciVision Biotech Inc
TW:1786
|
Taiwan | NT$2.75 Billion |
|
MEDIMI AB AK
F:79T
|
Germany | €1.79 Million |
|
Ansell Ltd
AU:ANN
|
Australia | AU$3.39 Billion |
|
Nanosonics Ltd
AU:NAN
|
Australia | AU$279.25 Million |
|
SDI Ltd
AU:SDI
|
Australia | AU$135.84 Million |
|
Austco Healthcare Ltd
AU:AHC
|
Australia | AU$91.07 Million |
Eyebright Medical Technology Beijing Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.11 | 4.48 | 11.03 |
| Quick Ratio | 2.47 | 3.43 | 10.50 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥1.32 Billion | CN¥962.62 Million | CN¥1.03 Billion |
Eyebright Medical Technology Beijing Co Ltd - Advanced Valuation Insights
This section examines the relationship between Eyebright Medical Technology Beijing Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.43 |
| Latest Market Cap to Assets Ratio | 0.32 |
| Asset Growth Rate (YoY) | 11.2% |
| Total Assets | CN¥3.89 Billion |
| Market Capitalization | $1.24 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Eyebright Medical Technology Beijing Co Ltd's assets below their book value (0.32x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Eyebright Medical Technology Beijing Co Ltd's assets grew by 11.2% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Eyebright Medical Technology Beijing Co Ltd (2016–2025)
The table below shows the annual total assets of Eyebright Medical Technology Beijing Co Ltd from 2016 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥3.89 Billion ≈ $568.92 Million |
+11.18% |
| 2024-12-31 | CN¥3.50 Billion ≈ $511.72 Million |
+14.21% |
| 2023-12-31 | CN¥3.06 Billion ≈ $448.04 Million |
+36.42% |
| 2022-12-31 | CN¥2.24 Billion ≈ $328.43 Million |
+9.61% |
| 2021-12-31 | CN¥2.05 Billion ≈ $299.63 Million |
+24.97% |
| 2020-12-31 | CN¥1.64 Billion ≈ $239.77 Million |
+138.93% |
| 2019-12-31 | CN¥685.78 Million ≈ $100.35 Million |
+16.94% |
| 2018-12-31 | CN¥586.45 Million ≈ $85.82 Million |
+112.43% |
| 2017-12-31 | CN¥276.06 Million ≈ $40.40 Million |
+18.28% |
| 2016-12-31 | CN¥233.39 Million ≈ $34.15 Million |
-- |
About Eyebright Medical Technology Beijing Co Ltd
Eyebright Medical Technology (Beijing) Co., Ltd. engages in development, production, and commercialization of ophthalmic medical devices in China and internationally. The company offers intraocular, trimmers, capsular tension ring, defocus lense, orthokeratology, and contact lenses in the areas of surgical treatment, myopia management, and consumer vision care. It also provides solutions for opht… Read more